Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Traul

Surgery Medford, OR Medical Doctor

NPI 1356422596 CMS profile 287766

520 Medical Center Dr, Ste 300, Medford, OR 97504

Open in the dashboard

General payments

$10,520

87 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Traul of Medford, OR is reported in the CMS Open Payments database as having received $10,520 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $157 8
2024 General $1,959 18
2023 General $427 10
2022 General $247 6
2021 General $126 6
2020 General $1,203 13
2019 General $6,401 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Traul
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to David Traul were reported at $157. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year David Traul Surgery median Middle half National median
2019 $6,401 $253 $82–$1,521 $163
2020 $1,203 $131 $40–$706 $114
2021 $126 $168 $50–$904 $132
2022 $247 $224 $76–$1,218 $149
2023 $427 $253 $82–$1,255 $160
2024 $1,959 $279 $90–$1,381 $164
2025 $157 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $9,680 59 payments
  2. W. L. Gore & Associates, Inc. $214 5 payments
  3. Boston Scientific Corporation $135 6 payments
  4. Silk Road Medical, Inc. $133 1 payment
  5. Medtronic, Inc. $104 4 payments
  6. Cook Medical LLC $85 5 payments
  7. Davol Inc. $56 2 payments
  8. Ethicon US, LLC $37 1 payment
  9. Tactile Systems Technology Inc $30 1 payment
  10. Abbott Laboratories $21 1 payment
  11. Other $25 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,722 15 payments
  2. Food and Beverage $3,289 70 payments
  3. Education $2,500 1 payment
  4. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $9,680 59 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $133 1 payment
  3. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $133 1 payment
  4. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $133 1 payment
  5. ENROUTE Transcarotid Stent $133 1 payment
  6. GORE EXCLUDER AAA Endoprosthesis $106 1 payment
  7. Zilver PTX $73 4 payments
  8. VENASEAL $68 2 payments
  9. JETSTREAM SC $53 3 payments
  10. Phasix Mesh $41 1 payment
  11. Other $337 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

188

Median for General Surgery: 59

Drug cost

$17,066

Median for General Surgery: $393

Branded share of claims

79.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $14,724
Clopidogrel Clopidogrel Bisulfate Brand 102 $1,534
Cilostazol Generic 38 $610
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $198

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 192 billing codes

Paid by Medicare

$450,648

Of which drugs: $18

Medicare patients

681

Average age 75

Services billed

2,135

334 women, 347 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 38%
Chronic kidney disease 33%
Diabetes 32%
Heart failure 29%
Atrial fibrillation 29%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fentanyl citrate, 0.1 mg J3010 Office 22 27 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record